IDEAYA Biosciences (IDYA) Depreciation & Amortization (CF) (2018 - 2026)
IDEAYA Biosciences (IDYA) reported Depreciation & Amortization (CF) of $688000.0 for Q1 2026, up 14.67% on a YoY basis from $600000.0 in Q1 2025, and down 4.58% sequentially from $721000.0 in Q4 2025.
IDEAYA Biosciences (IDYA) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
IDEAYA Biosciences (IDYA) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $688000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 14.67% year-over-year to $688000.0; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 17.59% YoY), and the FY2025 full-year result was $2.7 million, up 13.11% from the prior year.
- Depreciation & Amortization (CF) retreated to $688000.0 in Q1 2026, from $721000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $721000.0 in Q4 2025 to a low of $464000.0 in Q1 2022.
- A 5-year average of $608941.2 and a median of $616000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) increased 26.72% in 2023 and decreased 9.84% in 2024, its largest moves.
- Tracing IDYA's Depreciation & Amortization (CF) over 5 years: stood at $558000.0 in 2022, then gained by 12.72% to $629000.0 in 2023, then declined by 9.06% to $572000.0 in 2024, then advanced by 26.05% to $721000.0 in 2025, then retreated by 4.58% to $688000.0 in 2026.
- Business Quant data shows IDYA's Depreciation & Amortization (CF) at $688000.0 in Q1 2026, $721000.0 in Q4 2025, and $661000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | IDEAYA Biosciences | 3.21 Bn | 2.54 Bn | - | 688,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 688,000.00 |
| Mar 31, 2026 | 688,000.00 |
| Dec 31, 2025 | 721,000.00 |
| Dec 31, 2025 | 721,000.00 |
| Sep 30, 2025 | 661,000.00 |
| Sep 30, 2025 | 661,000.00 |
| Jun 30, 2025 | 718,000.00 |
| Jun 30, 2025 | 718,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 572,000.00 |
| Dec 31, 2024 | 572,000.00 |
| Sep 30, 2024 | 577,000.00 |
| Sep 30, 2024 | 577,000.00 |
| Jun 30, 2024 | 622,000.00 |
| Jun 30, 2024 | 622,000.00 |
| Mar 31, 2024 | 616,000.00 |
| Mar 31, 2024 | 616,000.00 |
| Dec 31, 2023 | 629,000.00 |
| Dec 31, 2023 | 629,000.00 |